Apollo AyurVAID, India’s NABH-accredited precision Ayurveda hospital network, announced its entry into the Ayurvedic products segment with a capital investment of ₹15 crore. The strategic expansion is aimed at complementing its existing inpatient-outpatient care model while unlocking scalable revenue opportunities.
In an official statement, Rajiv Vasudevan, Founder, MD, and CEO of Apollo AyurVAID, said, “This foray into the Ayurveda product vertical aligns with our vision of mainstreaming evidence-based Ayurveda by making both services and products accessible on a global scale. We anticipate this portfolio will be a key growth driver, targeting a revenue of ₹500 crore over the next five years.”
The new Ayurveda products division will operate as an independent business unit within Apollo AyurVAID. The product range will include classical Ayurvedic formulations (available via prescription), as well as OTC products and medical foods that will be distributed through a broad retail and digital network.
Highlighting expansion plans, Vasudevan stated, “In the current fiscal year, we aim to extend the Apollo AyurVAID footprint across India in an asset-light model, adding 9 new locations, increasing our bed capacity to 350, and targeting treatment for over 50,000 patients.”
With a compound annual growth rate (CAGR) of 75% over the past 2–3 years, Apollo AyurVAID is set to cross the ₹100 crore annualized revenue mark by mid-next year.
This development aligns with the rapid growth of India’s Ayurveda products market, currently valued at approximately ₹60,000 crore and expanding at a strong annual rate of over 16%. The market presents immense opportunities for innovative, evidence-based Ayurvedic companies like Deep Ayurveda, a leading manufacturer in India. Deep Ayurveda has made remarkable efforts in delivering authentic, result-oriented Ayurvedic medicines and has been instrumental in promoting traditional Ayurveda across global markets, especially in Australia, New Zealand, the USA, and Europe.
